The CJC-1295 Ipamorelin blend is one of the most frequently co-studied secretagogue pairings in growth-hormone (GH) research, because it combines two mechanistically distinct classes of compound that act on separate but convergent pathways in the somatotroph cell. CJC-1295 without DAC (also called Mod GRF 1-29) is a growth-hormone-releasing hormone (GHRH) analog, while Ipamorelin is a selective ghrelin-receptor agonist — a "growth-hormone secretagogue" that mimics ghrelin. Investigators pair them in laboratory and preclinical models to examine whether simultaneous stimulation of both axes reproduces or amplifies the endogenous pulsatile pattern of GH secretion more faithfully than either agent alone.
Research Use Only. This material is intended strictly for laboratory and in-vitro/preclinical research. It is not for human or veterinary use. It has not been evaluated by the FDA and is not intended to diagnose, treat, cure, or prevent any disease. Nothing here constitutes medical or dosing guidance. The information below describes mechanisms and published research directions only.
Two receptors, one convergent pathway
Growth hormone release from the anterior pituitary is governed by at least three overlapping signals. Understanding why CJC-1295 (no DAC) and Ipamorelin are studied together requires separating those signals.
- GHRH pathway: CJC-1295 without DAC is a modified fragment of GHRH(1-29). It binds the GHRH receptor (GHRHR), a Gs-coupled receptor that elevates intracellular cAMP and drives both synthesis and release of GH. Research models use it to probe GHRHR-mediated amplitude of the GH pulse.
- Ghrelin / GHS-R1a pathway: Ipamorelin selectively activates the growth-hormone secretagogue receptor (GHS-R1a), a Gq-coupled receptor that signals through phospholipase C and intracellular calcium. This is a mechanistically independent trigger for GH release.
- Somatostatin tone: Somatostatin is the inhibitory brake on GH. Ghrelin-receptor agonists such as Ipamorelin are studied in part because they appear to attenuate somatostatinergic tone, effectively "releasing the brake" while GHRH signaling "presses the accelerator."
Because the two receptors sit on different G-protein cascades (cAMP vs. calcium) and because Ipamorelin also modulates the inhibitory arm, preclinical work has examined whether the combination produces a synergistic rather than merely additive GH response. For a deeper treatment of this interaction, see GHRH + Ghrelin Synergy in GH Research.
Why "no DAC" specifically?
CJC-1295 exists in two research forms, and the distinction is central to why the no-DAC variant is chosen for this pairing. The DAC (Drug Affinity Complex) version incorporates a maleimidopropionic acid moiety that binds serum albumin, extending its half-life to roughly a week and producing a sustained "bleed" of GHRH signaling. The no-DAC form (Mod GRF 1-29) is short-acting, with a half-life measured in minutes.
For studies of pulsatile secretion, the short half-life is the point. Endogenous GH is not released as a flat plateau — it is secreted in discrete bursts. A short-acting GHRH analog produces a sharp, time-limited stimulus that more closely models a natural pulse, whereas the DAC version tends to elevate baseline GH more continuously. Researchers examining pulse amplitude, frequency, and the shape of the secretory episode typically select the no-DAC form. The trade-offs are compared directly in CJC-1295 With vs Without DAC, and the long-acting variant is covered in CJC-1295 with DAC: GHRH Analog Research.
Complementary kinetics as the rationale for co-administration
Ipamorelin is likewise relatively short-acting and, importantly, selective — unlike some earlier secretagogues, it shows minimal effect on cortisol, prolactin, or ACTH in published models, making it a "clean" tool for isolating the GHS-R1a contribution. Pairing a short GHRH pulse with a short ghrelin-mimetic pulse lets researchers deliver two synchronized, transient triggers and observe the resulting single, well-defined GH episode. Ipamorelin's selectivity profile is detailed in the Ipamorelin Research Guide.
Mechanism-of-action summary table
| Property | CJC-1295 (no DAC) | Ipamorelin |
|---|---|---|
| Class | GHRH analog (Mod GRF 1-29) | Ghrelin mimetic / GHS-R1a agonist |
| Receptor | GHRHR (Gs / cAMP) | GHS-R1a (Gq / PLC-Ca²⁺) |
| Primary research effect | Increases GH pulse amplitude | Triggers GH release; blunts somatostatin tone |
| Kinetics | Short (minutes) | Short (minutes) |
| Selectivity note | GHRHR-specific | Minimal cortisol/prolactin effect in models |
What preclinical research has examined
Studies involving GHRH analogs together with ghrelin-receptor agonists have investigated several questions relevant to endocrinology models:
- Amplitude vs. frequency: whether co-stimulation raises the height of GH pulses without disrupting their natural rhythm.
- Synergy quantification: whether combined GH output exceeds the sum of each agent applied separately — a signature of the two pathways relieving different constraints.
- Downstream IGF-1 signaling: GH acts on hepatic and peripheral tissue to influence insulin-like growth factor 1 (IGF-1); research models track this axis as a readout of sustained somatotropic activity.
- Receptor desensitization: how continuous vs. pulsatile stimulation affects GHS-R1a and GHRHR responsiveness over time.
These are experimental questions studied in cell culture and animal models. They are not statements about outcomes in humans.
Laboratory handling of the blend
The featured research preparation, CJC-1295 (no DAC) + Ipamorelin 5+5mg blend, is supplied as a co-lyophilized powder at ≥99% purity with a third-party COA. General laboratory handling for research preparations:
- Reconstitution: introduce bacteriostatic or sterile water down the vial wall; do not inject directly onto the powder pellet, and avoid vigorous agitation, which can shear peptide bonds. Swirl gently until dissolved.
- Storage: lyophilized material is stable refrigerated (or frozen for long-term); once reconstituted, store at 2-8 °C and protect from light and freeze-thaw cycles.
- Concentration math: because it is a fixed-ratio blend, both peptides reconstitute together — account for the combined mass when calculating working concentration for an assay.
Step-by-step protocol details are in Reconstituting Peptide Blends in the Lab. This is a member of the broader Peptide Blends & Combination Research pillar, which covers co-studied secretagogue pairings and stacking rationale in depth.
Sourcing considerations for reproducible research
Reproducibility in secretagogue studies depends heavily on material identity and purity — trace impurities or an incorrect peptide ratio in a blend can confound GH-response readouts. NeuroLabs supplies this research peptide at ≥99% purity with third-party COA verification and same-day USA shipping. For COA requests or research inquiries, contact neurolabsresearch3@gmail.com.